Financials DaBomb Protein Biotech Corp.

Equities

6578

TW0006578008

Food Processing

End-of-day quote Taipei Exchange 23:00:00 02/06/2024 BST 5-day change 1st Jan Change
28.75 TWD +2.86% Intraday chart for DaBomb Protein Biotech Corp. +2.68% +37.23%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 666.6 706.3 640.3 577.3 636.2 1,251
Enterprise Value (EV) 1 540.7 661.3 667.2 998.2 936.6 1,288
P/E ratio 24.6 x 33.5 x 88.5 x -9.07 x -13.9 x -19.7 x
Yield 3.5% 2.07% 0.94% - 4.13% 2.63%
Capitalization / Revenue 1.07 x 1.09 x 1.06 x 1.23 x 1.47 x 3.25 x
EV / Revenue 0.87 x 1.02 x 1.1 x 2.12 x 2.16 x 3.35 x
EV / EBITDA 12.7 x 12.3 x 17.2 x -25.1 x -25 x -129 x
EV / FCF -3.73 x -14.5 x -11.5 x -2.69 x 25.2 x -4.29 x
FCF Yield -26.8% -6.9% -8.68% -37.2% 3.97% -23.3%
Price to Book 0.94 x 1.02 x 0.91 x 0.86 x 0.87 x 1.31 x
Nbr of stocks (in thousands) 32,091 32,170 33,145 33,082 39,514 59,710
Reference price 2 20.77 21.95 19.32 17.45 16.10 20.95
Announcement Date 28/03/19 31/03/20 24/03/21 29/03/22 29/03/23 29/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 622.8 646.6 605.2 470.6 433.6 384.4
EBITDA 1 42.61 53.89 38.82 -39.81 -37.48 -9.98
EBIT 1 31.24 39.13 15.39 -63.77 -62.47 -29.93
Operating Margin 5.02% 6.05% 2.54% -13.55% -14.41% -7.79%
Earnings before Tax (EBT) 1 33.53 31.7 11.63 -71.62 -49.06 -55.95
Net income 1 25.14 21.19 7.193 -62.45 -44.66 -57.02
Net margin 4.04% 3.28% 1.19% -13.27% -10.3% -14.83%
EPS 2 0.8455 0.6545 0.2182 -1.923 -1.154 -1.066
Free Cash Flow 1 -145 -45.66 -57.95 -371.6 37.17 -300.2
FCF margin -23.27% -7.06% -9.57% -78.95% 8.57% -78.1%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.7273 0.4545 0.1819 - 0.6650 0.5500
Announcement Date 28/03/19 31/03/20 24/03/21 29/03/22 29/03/23 29/03/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 26.9 421 300 37.5
Net Cash position 1 126 45 - - - -
Leverage (Debt/EBITDA) - - 0.6937 x -10.57 x -8.016 x -3.761 x
Free Cash Flow 1 -145 -45.7 -57.9 -372 37.2 -300
ROE (net income / shareholders' equity) 3.77% 3.01% 1.03% -9.08% -6.37% -6.77%
ROA (Net income/ Total Assets) 2.31% 2.78% 0.97% -3.33% -2.98% -1.39%
Assets 1 1,090 763.2 739.2 1,875 1,497 4,088
Book Value Per Share 2 22.10 21.60 21.10 20.40 18.40 16.00
Cash Flow per Share 2 6.210 6.390 8.010 5.960 4.940 6.360
Capex 1 163 91.8 17.8 332 20 18.9
Capex / Sales 26.18% 14.2% 2.94% 70.56% 4.61% 4.91%
Announcement Date 28/03/19 31/03/20 24/03/21 29/03/22 29/03/23 29/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. 6578 Stock
  4. Financials DaBomb Protein Biotech Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW